Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?
Prostate cancer invokes major shifts in gene transcription and metabolic signaling to mediate alterations in nutrient acquisition and metabolic substrate selection when compared to normal tissues. Exploiting such metabolic reprogramming is proposed to enable the development of targeted therapies for...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.778761/full |
| _version_ | 1798016126802722816 |
|---|---|
| author | Gio Fidelito Matthew J. Watt Renea A. Taylor Renea A. Taylor Renea A. Taylor |
| author_facet | Gio Fidelito Matthew J. Watt Renea A. Taylor Renea A. Taylor Renea A. Taylor |
| author_sort | Gio Fidelito |
| collection | DOAJ |
| description | Prostate cancer invokes major shifts in gene transcription and metabolic signaling to mediate alterations in nutrient acquisition and metabolic substrate selection when compared to normal tissues. Exploiting such metabolic reprogramming is proposed to enable the development of targeted therapies for prostate cancer, yet there are several challenges to overcome before this becomes a reality. Herein, we outline the role of several nutrients known to contribute to prostate tumorigenesis, including fatty acids, glucose, lactate and glutamine, and discuss the major factors contributing to variability in prostate cancer metabolism, including cellular heterogeneity, genetic drivers and mutations, as well as complexity in the tumor microenvironment. The review draws from original studies employing immortalized prostate cancer cells, as well as more complex experimental models, including animals and humans, that more accurately reflect the complexity of the in vivo tumor microenvironment. In synthesizing this information, we consider the feasibility and potential limitations of implementing metabolic therapies for prostate cancer management. |
| first_indexed | 2024-04-11T15:44:52Z |
| format | Article |
| id | doaj.art-883e3065ed4d4ce2b2dda621755f57eb |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T15:44:52Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-883e3065ed4d4ce2b2dda621755f57eb2022-12-22T04:15:36ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-01-011110.3389/fonc.2021.778761778761Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?Gio Fidelito0Matthew J. Watt1Renea A. Taylor2Renea A. Taylor3Renea A. Taylor4Department of Anatomy & Physiology, The University of Melbourne, Melbourne, VIC, AustraliaDepartment of Anatomy & Physiology, The University of Melbourne, Melbourne, VIC, AustraliaDepartment of Physiology, Biomedicine Discovery Institute, Cancer Program, Monash University, Melbourne, VIC, AustraliaProstate Cancer Research Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, AustraliaProstate cancer invokes major shifts in gene transcription and metabolic signaling to mediate alterations in nutrient acquisition and metabolic substrate selection when compared to normal tissues. Exploiting such metabolic reprogramming is proposed to enable the development of targeted therapies for prostate cancer, yet there are several challenges to overcome before this becomes a reality. Herein, we outline the role of several nutrients known to contribute to prostate tumorigenesis, including fatty acids, glucose, lactate and glutamine, and discuss the major factors contributing to variability in prostate cancer metabolism, including cellular heterogeneity, genetic drivers and mutations, as well as complexity in the tumor microenvironment. The review draws from original studies employing immortalized prostate cancer cells, as well as more complex experimental models, including animals and humans, that more accurately reflect the complexity of the in vivo tumor microenvironment. In synthesizing this information, we consider the feasibility and potential limitations of implementing metabolic therapies for prostate cancer management.https://www.frontiersin.org/articles/10.3389/fonc.2021.778761/fullprostate neoplasialipid metabolismobesitymetabolismpatient-derived xenograftmetabolic targeting |
| spellingShingle | Gio Fidelito Matthew J. Watt Renea A. Taylor Renea A. Taylor Renea A. Taylor Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? Frontiers in Oncology prostate neoplasia lipid metabolism obesity metabolism patient-derived xenograft metabolic targeting |
| title | Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? |
| title_full | Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? |
| title_fullStr | Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? |
| title_full_unstemmed | Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? |
| title_short | Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? |
| title_sort | personalized medicine for prostate cancer is targeting metabolism a reality |
| topic | prostate neoplasia lipid metabolism obesity metabolism patient-derived xenograft metabolic targeting |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.778761/full |
| work_keys_str_mv | AT giofidelito personalizedmedicineforprostatecanceristargetingmetabolismareality AT matthewjwatt personalizedmedicineforprostatecanceristargetingmetabolismareality AT reneaataylor personalizedmedicineforprostatecanceristargetingmetabolismareality AT reneaataylor personalizedmedicineforprostatecanceristargetingmetabolismareality AT reneaataylor personalizedmedicineforprostatecanceristargetingmetabolismareality |